ALS Treatment Composition Combining NAD+, Antioxidant, PDE4, and Thiol Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for motor neuron diseases like ALS have shown limited therapeutic benefits, with anti-inflammatory drugs such as glucocorticoids and cyclooxygenase 2 inhibitors failing to provide significant clinical benefits, and existing therapies lacking effective methods to slow or reverse motor neuron degeneration.
Innovation Solution
Administering a composition comprising nicotinamide riboside, pterostilbene, and a phosphodiesterase (PDE) inhibitor, such as ibudilast, optionally with acetylcysteine, to treat motor neuron diseases, enhancing treatment efficacy through synergistic interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-inflammatory drugs such as glucocorticoids and cyclooxygenase 2 inhibitors are administered, then inflammation is reduced, but therapeutic benefit is not achieved
Solution Approach 1:
The patent combines multiple compounds with different mechanisms of action (nicotinamide riboside for mitochondrial function, pterostilbene for antioxidant activity, PDE4 inhibitor for anti-inflammatory effects, and acetylcysteine for glutathione replenishment) into a single composition. This multi-component approach addresses both inflammation and the underlying mitochondrial dysfunction, achieving therapeutic benefit that single agents failed to provide
Solution Approach 2:
The invention uses a composite therapeutic formulation containing four distinct active compounds, each targeting different pathological aspects of ALS. This composite approach creates a synergistic effect where the combination of agents produces greater therapeutic benefit than any single component alone, resolving the contradiction between reducing inflammation and achieving meaningful therapeutic benefit
2Ease of operation
If existing therapies are used, then treatment is provided, but motor neuron degeneration is not effectively slowed or reversed
Solution Approach 1:
The patent employs compounds that act preventively and protectively against motor neuron degeneration. Nicotinamide riboside replenishes NAD+ stores before mitochondrial failure occurs, pterostilbene provides antioxidant protection before oxidative damage accumulates, and acetylcysteine maintains glutathione levels before neuronal vulnerability increases. This preliminary protective action slows degeneration effectively while maintaining treatment feasibility
Solution Approach 2:
The invention targets fundamental biochemical parameters in motor neurons: NAD+ levels, mitochondrial membrane potential, oxidative stress markers, and glutathione concentrations. By restoring these critical parameters to healthy ranges, the treatment effectively slows motor neuron degeneration. The multi-parameter approach ensures comprehensive protection against diverse degenerative mechanisms
3Device complexity
If single agents are administered, then treatment simplicity is maintained, but synergistic effect is not achieved
Solution Approach 1:
The patent merges four distinct therapeutic agents into a single coordinated composition, each targeting different pathological pathways in ALS. The combination includes nicotinamide riboside (mitochondrial support), pterostilbene (antioxidant), PDE4 inhibitor (anti-inflammatory), and acetylcysteine (glutathione precursor). This merging creates synergistic interactions that produce treatment efficacy exceeding the sum of individual effects, resolving the contradiction between simplicity and effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly improves survival and functional outcomes in mouse models of ALS, demonstrating a synergistic effect that surpasses individual treatments, with enhanced motor neuron function and prolonged survival.
Implementation Method 1
Mendelsohn and Larrick (2014) showed that treatment of moderately old mice (first-phase OXPHOS defects) with nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) for 1 week restores oxidative phosphorylation activity and other markers of mitochondrial function in skeletal muscle
Implementation Method 2
Cheng Y, Di S, Fan C, Cai L, Gao C, Jiang P, Hu W, Ma Z, Jiang S, Dong Y, Li T, Wu G, Lv J, Yang Y. SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury
Implementation Method 3
SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury
Implementation Method 4
Ibudilast (development codes: AV-411 or MN-166) is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent
Implementation Method 5
In additional embodiments, a thiol/cysteine donor, such as acetylcysteine can also be added to the composition and/or administered to the subjects to further enhance the treatment
Data Source
AI summary
Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside, pterostilbene and a phosphodiesterase (PDE) inhibitor, including a PDE4 inhibitor such as ibudilast, and also including a thiol/cysteine donor, such as acetylcysteine.